Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
Read Now: TheBodyPRO.com Covers AIDS 2014
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

U.S. News

Bristol-Myers Squibb Cites Positive Data in Retreatment of Hepatitis B Using Baraclude

April 16, 2007

On Friday, Bristol-Myers Squibb reported its drug Baraclude was effective in retreating patients with recurrent levels of hepatitis B virus. In a cohort study, the drug maker said 93 percent of patients who had previously taken Baraclude but whose treatment was interrupted were able to suppress the virus by using the drug again for 48 weeks. The Food and Drug Administration approved Baraclude in 2005.

Back to other news for April 2007

Adapted from:
Associated Press
04.13.2007


  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
 
See Also
More HIV News

Tools
 

Advertisement